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(MPD) plans. METHODS: Fifty patients were randomly selected
from a database of 18,000 Medicare-eligible patients provided
by a pharmacy beneﬁts management company. Each patient’s
medication history from January–June 2007 was used to gener-
ate their medication proﬁle. Each proﬁle was entered into the
Medicare website and the EAC were calculated. For each patient
the lowest, mean, and highest EAC were obtained for both 2007
and 2008 in each of the 34 MPD regions. EAC from 2007 were
inﬂation-adjusted and compared to 2008 costs. Pair-wise com-
parisons were performed to analyze unadjusted and inﬂation-
adjusted 2007 versus 2008 EAC differences within each region.
RESULTS: In some regions, signiﬁcant increases were observed
in the comparisons of 2007 EAC or inﬂation-adjusted 2007 EAC
versus 2008 EAC. For example, in California all 2008 EAC
values (lowest, mean, and highest) signiﬁcantly increased from
2007 (both unadjusted and inﬂation-adjusted). This differed
from other regions where there was no change or a decrease in
EAC was observed. For example, in Alaska the lowest EAC were
not statistically different between 2008 and 2007 (both unad-
justed and inﬂationadjusted). Mean EAC showed a signiﬁcant
decrease only when 2007 EAC were inﬂation adjusted, while
highest 2007 EAC values (both unadjusted and inﬂation-
adjusted) were signiﬁcantly greater than the highest 2008 EAC.
CONCLUSION: The privatization of MPD plans was intended
to decrease drug acquisition costs and theoretically these savings
would decrease drug costs for Medicare-eligible patients.
However, based on the variable trends between MPD regions,
and in some instances the increase in EAC from 2007 to 2008,
drug costs incurred by patients do not appear to be decreasing
between 2007 and 2008.
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OBJECTIVE: The study objectives were to describe the charac-
teristics and quality of health economics (including pharmaco-
economics) evaluation research studies related to Zimbabwe.
METHODS: A literature review was conducted to identify health
economic evaluation articles. Health economics evaluation,
PUBMED, MEDLINE, HealthSTAR, EconLit, and Psychinfo
databases and sociological and dissertation abstracts were used
to search economic analyses. Only original applied economic
evaluations addressing a health-related topic related to Zimba-
bwe and published in peer reviewed journals in the English
language were included. Two reviewers independently evaluated
and scored each article in the ﬁnal sample. RESULTS: The 25
identiﬁed articles, published between 1987 and 2005, appeared
in 13 different journals (based mostly outside of Zimbabwe). On
average, each article was written by three authors, who had
mostly medical/clinical training. The number of articles peaked
between 1993 and 1997. Based on a 1 to 10 scale, with 10
indicating the highest quality, the mean quality score for all
studies was 5.36 (SD = 1.57) and about one-third of the articles
were of poor quality (score < 4). The quality of articles was
statistically signiﬁcantly related (p < 0.10) to the country of
journal (non-Zimbabwe = higher), type of publication (non-
medical = higher), number of authors (more authors = higher),
years of publication (more recent = higher), and primary health
intervention (services higher than pharmaceutical interventions).
The quality of the articles was not signiﬁcantly related to the
country of current residence of the primary authors, sample size,
primary training of the ﬁrst author, main objective of the study,
and type of data (primary vs secondary). CONCLUSION: The
results of the study indicated that the use of health economics
(including pharmacoeconomics) evaluation research in Zimba-
bwe is limited and about one-third of published articles were of
poor quality. More and better quality health economics research
in Zimbabwe is warranted.
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OBJECTIVE: To develop a theoretical framework and process to
deﬁne and identify pharmacist-sensitive outcomes for chronic
diseases and propose how these can be operationalized within
practice, policy, and research. METHODS: A collaborative medi-
cation management framework was developed to provide a
platform for identifying outcomes sensitive to pharmacists’ con-
tribution to patient’s care. Potential indicators for speciﬁc phar-
macist’s roles identiﬁed were: supporting medication-prescribing
practice; medication-taking practice; and medication-related
information transfer. Clinical indicators of potential impact on
patient’s outcomes were noted. The framework was used to
structure gathering, selecting, and processing of literature-based
information. We searched IPA, Medline, and Embase (inception-
2006) to identify research describing the impact of pharmacists’
patient-care interventions. Two independent reviewers identiﬁed
articles, then extracted data; results were compared and settled
through consensus. Articles were grouped by disease. Outcomes/
indicators were categorized as deﬁnitely sensitive, probably sen-
sitive, probably not sensitive, or deﬁnitely not pharmacist-
sensitive. Data extracted included intervention type, patient
numbers, demographics, study characteristics, instruments used,
data compared, and outcomes. Where sufﬁcient, data were
combined in a random-effects meta-analysis. Study quality
was assessed using Downs-Black scale. RESULTS: The
framework and the methodology developed are effective
in synthesizing and interpreting literature data to identify
pharmacist-sensitive outcomes. Average study quality was
62%  11% (“fair”). Signiﬁcant impacts were found on reduc-
ing glycosylated hemoglobin (0.62%  0.29%; N = 2247;
k = 16; P = 0.03) and systolic blood pressure (6.93.5 mmHg;
N = 2246; k = 13; P = 0.047). Non-sensitive were diastolic blood
pressure (3.6  1.9 mmHg; N = 2246; k = 13; P = 0.06), quality
of life (1/8 signiﬁcant) and compliance (5/13 signiﬁcant). CON-
CLUSION: Pharmacist-sensitive outcomes identiﬁed to date are
for diabetes and hypertension (in progress are asthma-COPD,
congestive heart failure, mental illnesses and arthritis). More
research studies are required to verify the signiﬁcance of ﬁndings.
Pharmacist-sensitive outcomes is an underdeveloped concept.
Current studies primarily assess clinical outcomes and few
measure indicators that are more proximal to a pharmacist
intervention.
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OBJECTIVE: 1) To identify clusters of African-American (AA)
CAM users based on their past 12 month usage of 17 CAM
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